Claritas Pharmaceuticals Inc V.CLAS.H

NEWS: Kalytera to complete name, symbol change April 12

[Amazigh]

Kalytera to complete name, symbol change April 12 2021-04-07 19:07 ET - News Release Mr. Robert Farrell reports NAME CHANGE TO CLARITAS PHARMACEUTICALS, INC. Kalytera Therapeutics Inc. is changing its name to Claritas Pharmaceuticals Inc. The name change will become effective, and the common shares of the company will begin trading under the new name, effective on April 12, 2021. The name change is subject to final TSX Venture Exchange approval. About the name change The decision to rename the company signals the relaunch of the company, and its intent to focus on the development of its proprietary drug, R-107, for the treatment of vaccine-resistant strains of COVID-19, as well as other viral infections. R-107 is a nitric-oxide-releasing molecule designed to treat vaccine-resistant COVID-19 infection, as well as the viruses that cause influenza and the common cold. The company's ticker symbol will change as a result of the name change. Effective April 12, 2021, the new ticker symbol will be CLAS. Shareholders will receive letters of transmittal from the company's transfer agent, which will also be posted on SEDAR and which can be used to exchange their current share certificates for certificates with the company's new name. Shareholders holding shares in electronic form need not take any action. All shareholders should refer to the letter of transmittal and instructions from their broker/dealer. The company's new Cusip and ISIN numbers for the company's active listed securities under its new name are the following. Common shares: ISIN: CA1806341071 and Cusip: 180634107 Warrants designated as WT: ISIN: CA1806341154 and Cusip: 180634115 Warrants designated as WTS22: ISIN: CA1806341238 and Cusip: 180634123 About Claritas Pharmaceuticals Inc. Claritas is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for patients with significant unmet medical needs. Claritas focuses on areas of unmet medical need and leverages its expertise to find solutions that will improve health outcomes and dramatically improve people's lives. We seek Safe Harbor.